Researchers have engineered macrophages to effectively target melanoma cells, advancing immunotherapy strategies against one of the deadliest skin cancers. This novel cell engineering approach enhances the innate immune response, offering personalized therapeutic potential. The study, published in the Journal of Translational Medicine, signals a promising frontier in leveraging immune cell modification to improve clinical outcomes in melanoma patients.